Cwm, LLC Fate Therapeutics Inc Transaction History

Cwm, LLC

  • $23.3 Billion
  • Q3 2024

A detailed history of Cwm, LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Cwm, LLC holds 868 shares of FATE stock, worth $1,440. This represents 0.0% of its overall portfolio holdings.

Number of Shares
868
Previous 630 37.78%
Holding current value
$1,440
Previous $2,000 50.0%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 08, 2024
BUY
$3.12 - $5.57 $742 - $1,325
238 Added 37.78%
868 $3,000
Q2 2024

Jul 09, 2024
BUY
$3.26 - $7.08 $260 - $566
80 Added 14.55%
630 $2,000
Q1 2024

Apr 05, 2024
BUY
$3.54 - $8.35 $21 - $50
6 Added 1.1%
550 $4,000
Q4 2023

Feb 01, 2024
SELL
$1.65 - $3.94 $3,811 - $9,101
-2,310 Reduced 80.94%
544 $2,000
Q3 2023

Oct 11, 2023
BUY
$2.02 - $5.04 $2,335 - $5,826
1,156 Added 68.08%
2,854 $6,000
Q2 2023

Aug 03, 2023
BUY
$4.76 - $6.59 $3,684 - $5,100
774 Added 83.77%
1,698 $8,000
Q1 2023

Apr 28, 2023
SELL
$4.24 - $11.12 $4,473 - $11,731
-1,055 Reduced 53.31%
924 $5,000
Q4 2022

Feb 01, 2023
BUY
$9.86 - $23.83 $10,560 - $25,521
1,071 Added 117.95%
1,979 $20,000
Q3 2022

Oct 27, 2022
BUY
$21.04 - $36.06 $1,136 - $1,947
54 Added 6.32%
908 $20,000
Q2 2022

Jul 28, 2022
BUY
$17.78 - $42.39 $14,899 - $35,522
838 Added 5237.5%
854 $21,000
Q1 2022

Apr 21, 2022
BUY
$29.67 - $60.28 $356 - $723
12 Added 300.0%
16 $1,000
Q4 2021

Jan 31, 2022
BUY
$47.84 - $64.34 $191 - $257
4 New
4 $0

Others Institutions Holding FATE

# of Institutions
175
Shares Held
115M
Call Options Held
53.7K
Put Options Held
9K
View Full List

About FATE THERAPEUTICS INC

FATE Quotes by TradingView
  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $161M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Cwm, LLC Portfolio

Follow Cwm, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email